Kinetics of morphine in patients with renal failure.

Long lasting respiratory depression induced by morphine-6-glucuronide? Br J Clin Pharmacol (1989) 0.99

Renal failure does not impair the metabolism of morphine. Br J Clin Pharmacol (1986) 0.87

Pharmacokinetics of Morphine and Its Metabolites in Infants and Young Children After Congenital Heart Surgery. AAPS J (2015) 0.76

Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96

Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med (1978) 2.68

Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26

Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07

Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76

Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol (1974) 1.44

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41

The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesiol Scand (1998) 1.40

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37

High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet (1986) 1.34

Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol (1983) 1.33

Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol (1982) 1.24

Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol (1985) 1.23

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21

Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc (1998) 1.19

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther (1989) 1.17

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13

Morphine kinetics in cancer patients. Clin Pharmacol Ther (1981) 1.12

Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol (1976) 1.12

Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol (1989) 1.12

Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol (1989) 1.11

The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol (1990) 1.11

Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol (1991) 1.10

Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit (1997) 1.10

Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol (1983) 1.08

Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet (1993) 1.08

Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol (1987) 1.04

Gallstones, cholecystectomy, and duodenogastric reflux of bile acid. Scand J Gastroenterol (1986) 1.04

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS (1999) 1.03

High-performance liquid chromatographic method for determination of amodiaquine, chloroquine and their monodesethyl metabolites in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.03

Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia (2011) 1.01

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther (1996) 1.00

Long lasting respiratory depression induced by morphine-6-glucuronide? Br J Clin Pharmacol (1989) 0.99

Glucuronidation of morphine in human liver and interaction with oxazepam. Acta Anaesthesiol Scand Suppl (1982) 0.98

Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid. Clin Pharmacol Ther (1976) 0.98

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation (1998) 0.98

Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol (1999) 0.96

Oxazepam disposition in uremic patients. Acta Pharmacol Toxicol (Copenh) (1977) 0.96

Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit (2000) 0.95

Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients. Eur J Clin Pharmacol (1975) 0.95

Nonlinearity of amoxicillin absorption kinetics in human. Eur J Clin Pharmacol (1992) 0.95

Protein binding of diazepam and digitoxin in uremic and normal serum. Biochem Pharmacol (1979) 0.94

Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics (1995) 0.94

Changing pattern in aetiology of pancreatitis in an urban Swedish area. Br J Surg (1979) 0.94

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther (2001) 0.93

Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther (2001) 0.93

Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol (1990) 0.93

Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1997) 0.91

High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients. Lancet (1984) 0.91

Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther (1995) 0.91

Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol (1991) 0.91

Systemic and central effects of morphine on gastroduodenal motility. Acta Anaesthesiol Scand (1996) 0.91

Anal implantation metastasis from carcinoma of the sigmoid colon and rectum--a risk when performing anterior resection with the EEA stapler? Br J Surg (1985) 0.90

Cancer of the head of the pancreas and choledochoduodenal junction: a clinical study of 88 Whipple resections. Acta Chir Scand (1981) 0.88

Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection. Transplantation (1985) 0.88

Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit (1989) 0.88

In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per Aerosol). Pulm Pharmacol Ther (2004) 0.87

Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol (2002) 0.87

Duodenogastric reflux after gastric surgery. Scand J Gastroenterol (1983) 0.87

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol (2001) 0.86

Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther (1986) 0.86

A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br J Clin Pharmacol (1991) 0.85

Abnormal pharmacokinetics of phenytoin in a patient with uraemia. Lancet (1970) 0.85

Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal. Eur J Clin Pharmacol (1989) 0.85

Pharmacological treatment of cancer pain with special reference to the oral use of morphine. Acta Anaesthesiol Scand Suppl (1982) 0.85

Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism. Clin Pharmacol Ther (1984) 0.84

Natural (-)- and unnatural (+)-enantiomers of morphine: comparative metabolism and effect of morphine and phenobarbital treatment. J Pharmacol Exp Ther (1985) 0.84

Plasma protein binding of propranolol in disease states [proceedings]. Br J Clin Pharmacol (1977) 0.84

Metabolic interaction between morphine and various benzodiazepines. Acta Pharmacol Toxicol (Copenh) (1986) 0.83

Determination of ketobemidone and its metabolites in plasma and urine using solid-phase extraction and liquid chromatography-mass spectrometry. Ther Drug Monit (2001) 0.83

Glucuronidation of morphine in human kidney microsomes. Pharmacol Toxicol (1988) 0.83

Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. Pharmacol Toxicol (1996) 0.82

Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet (1998) 0.82

Carbamazepine-10,11-epoxide in epilepsy. A pilot study. Arch Neurol (1990) 0.81

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol (2001) 0.81

Comparative disposition of pethidine and norpethidine in old and young patients. Eur J Clin Pharmacol (1982) 0.81

Extradural morphine gives better pain relief than patient-controlled i.v. morphine after hysterectomy. Br J Anaesth (1997) 0.81

Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics (1997) 0.80

Pethidine binding to blood cells and plasma proteins in old and young subjects. Eur J Clin Pharmacol (1982) 0.80

Acute cardiac failure during treatment with digitoxin--an interaction with rifampicin. Br J Clin Pharmacol (1980) 0.80

Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J Clin Psychopharmacol (2000) 0.80

Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther Drug Monit (1997) 0.79

A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc (1996) 0.79

Ion-pair high-performance liquid chromatographic determination of isoniazid and acetylisoniazid in plasma and urine. Application for acetylator phenotyping. J Chromatogr (1985) 0.79

Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol (1997) 0.79

Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J (Clin Res Ed) (1981) 0.79

Gastric and intestinal mucosal morphology before and after interposition of a reflux-preventing valve between the gastric remnant and the duodenum. An experimental study in dogs. Acta Chir Scand (1980) 0.79